$4.11
+0.02 (+0.49%)
Open$4.18
Previous Close$4.09
Day High$4.59
Day Low$3.79
52W High$6.60
52W Low$1.60
Volume—
Avg Volume1.66M
Market Cap297.45M
P/E Ratio22.41
EPS$-1.42
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+664.2% upside
Current
$4.11
$4.11
Target
$31.41
$31.41
$26.29
$31.41 avg
$48.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 92.27M | 83.15M | 89.97M |
| Net Income | 5.58M | 4.38M | 5.69M |
| Profit Margin | 6.1% | 5.3% | 6.3% |
| EBITDA | 11.07M | 10.58M | 10.22M |
| Free Cash Flow | 5.66M | 4.59M | 4.29M |
| Rev Growth | -8.1% | +18.1% | +3.5% |
| Debt/Equity | 0.85 | 0.76 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |